Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma
在患有 H3 K27M 突变型胶质瘤的儿科患者中,每周连续两天服用 ONC201(多达韦普隆)的安全性和药代动力学研究
期刊:Neuro-Oncology
影响因子:13.4
doi:10.1093/neuonc/noae001
Odia, Yazmin; Koschmann, Carl; Vitanza, Nicholas A; de Blank, Peter; Aguilera, Dolly; Allen, Jeffrey; Daghistani, Doured; Hall, Matthew; Khatib, Ziad; Kline, Cassie; MacDonald, Tobey; Mueller, Sabine; Faison, Shamia L; Allen, Joshua E; Naderer, Odin J; Ramage, Samuel C; Tarapore, Rohinton S; McGovern, Susan Lynne; Khatua, Soumen; Zaky, Wafik; Gardner, Sharon L